Drug Price Trends for FT ANTI-ITCH

Average Pharmacy Cost for FT ANTI-ITCH

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
FT ANTI-ITCH 2%-0.1% CREAM	70677-1213-01	0.06667	GM	2024-12-18
FT ANTI-ITCH 2%-0.1% CREAM	70677-1213-01	0.06679	GM	2024-11-20
FT ANTI-ITCH 2%-0.1% CREAM	70677-1213-01	0.06641	GM	2024-10-23
FT ANTI-ITCH 2%-0.1% CREAM	70677-1213-01	0.06932	GM	2024-09-18
FT ANTI-ITCH 2%-0.1% CREAM	70677-1213-01	0.07088	GM	2024-08-21

FT ANTI-ITCH Market Analysis and Financial Projection

Market Analysis and Price Projections for Anti-Itch Drugs: A Comprehensive Overview

Introduction to Anti-Itch Drugs

Anti-itch drugs, including creams, ointments, and oral medications, are a crucial segment of the pharmaceutical and healthcare industries. These products are designed to alleviate the discomfort, irritation, and itching associated with various dermatological conditions such as eczema, psoriasis, and allergic reactions.

Market Size and Growth Projections

The market for anti-itch treatments is experiencing significant growth driven by several key factors.

• Global Pruritus Therapeutics Market: The global pruritus therapeutics market was valued at USD 8.39 billion in 2022 and is expected to grow at a CAGR of 4.0% from 2023 to 2030, reaching USD 11.38 billion by 2030[3].
• U.S. Pruritus Treatment Market: In the United States, the pruritus treatment market was estimated at USD 5.1 billion in 2022 and is anticipated to reach USD 8.4 billion by 2031, growing at a CAGR of 5.6% from 2023 to 2031[1][4].
• Anti-Itch Cream Market: The global anti-itch cream market was valued at USD 5.2 billion in 2023 and is expected to reach USD 10.8 billion by 2030, with a CAGR of 8% during the forecast period[2].

Drivers of Market Growth

Several factors are driving the growth of the anti-itch drug market:

• Increasing Prevalence of Skin Diseases: Conditions such as atopic dermatitis, urticaria, and psoriasis are becoming more prevalent, driving the demand for anti-itch treatments[3].
• Rise in Geriatric Population: The increasing geriatric population is another significant driver, as older individuals are more prone to skin conditions that require anti-itch medications[4].
• Advancements in Therapies: The introduction of innovative therapies, including immunosuppressants, topical corticosteroids, and antihistamines, is boosting market growth[1].
• Growing Demand for OTC Medications: The rise in demand for over-the-counter (OTC) medications and the increasing adoption of telemedicine are providing lucrative opportunities for market players[1][4].

Market Segmentation

The anti-itch drug market is segmented based on several criteria:

• Pruritus Type: This includes systemic diseases, skin diseases (such as eczema and atopic dermatitis), neurologic diseases, and nocturnal pruritus[1][4].
• Drug Type: Key segments include antihistamines, calcineurin inhibitors, selective serotonin reuptake inhibitors, corticosteroids, and calamine[1][4].
• Geography: The market is classified into regions such as North America, Europe, Asia Pacific, and the rest of the world[2].

Key Players and Competitive Landscape

The market for anti-itch drugs is highly competitive, with several major players:

• AbbVie, Inc. (Allergan plc)
• Albireo Pharma, Inc.
• Astellas Pharma Inc.
• Cipla Limited
• Eli Lilly and Company
• GSK plc
• Merck & Co., Inc.
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc. (Mylan N.V.)[1][4].

Other notable players in the anti-itch cream market include Aveeno, POLYSPORIN, CeraVe, BENADRYL, and VANICREAM[2].

Challenges and Restraints

Despite the growth, the market faces several challenges:

• High Cost of Treatment: The high cost of some treatments is a significant restraint, limiting access to these medications for many patients[1][4].
• Adverse Effects: Some anti-itch medications are associated with adverse effects, which can deter patients and healthcare providers from using them[1].

Price Projections and Revenue Forecasts

The revenue forecasts for the anti-itch drug market are promising:

• U.S. Pruritus Treatment Market: Expected to reach USD 8.4 billion by 2031, growing at a CAGR of 5.6% from 2023 to 2031[1][4].
• Global Anti-Itch Cream Market: Expected to reach USD 10.8 billion by 2030, with a CAGR of 8% during the forecast period[2].
• Global Pruritus Therapeutics Market: Expected to reach USD 11.38 billion by 2030, growing at a CAGR of 4.0% from 2023 to 2030[3].

Impact of New Product Launches

New product launches are a key factor in driving market growth. For example, the approval of Bylvay (odevixibat) by the U.S. FDA in July 2021 for the treatment of pruritus in progressive familial intrahepatic cholestasis (PFIC) has expanded treatment options for patients[1].

Telemedicine and OTC Demand

The increasing adoption of telemedicine and the growing demand for OTC medications are offering lucrative opportunities for market players. Companies are focusing on developing affordable and effective OTC treatments to increase their market share and presence[1][4].

Regional Market Analysis

The market is geographically segmented, with different regions showing varying growth rates:

• North America: This region is expected to dominate the market due to high awareness and the presence of major pharmaceutical companies[2].
• Europe and Asia Pacific: These regions are also expected to show significant growth driven by increasing healthcare spending and a rising prevalence of skin diseases[2].

Key Takeaways

• The anti-itch drug market is growing significantly due to the increasing prevalence of skin diseases and the introduction of new therapies.
• The U.S. pruritus treatment market and the global anti-itch cream market are expected to reach USD 8.4 billion and USD 10.8 billion by 2031 and 2030, respectively.
• Major players are focusing on developing OTC medications and leveraging telemedicine to expand their market presence.
• High treatment costs and adverse effects are key restraints that need to be addressed.

Frequently Asked Questions (FAQs)

1. What is the projected growth rate of the U.S. pruritus treatment market?

The U.S. pruritus treatment market is expected to grow at a CAGR of 5.6% from 2023 to 2031[1][4].

2. Which segment dominates the pruritus therapeutics market?

Corticosteroids dominated the pruritus therapeutics market with a share of 24.1% in 2022[3].

3. What are the key drivers of the anti-itch cream market?

The key drivers include the increasing prevalence of skin diseases, the rise in geriatric population, and the growing demand for OTC medications[2][3].

4. Who are the major players in the anti-itch drug market?

Major players include AbbVie, Inc., Albireo Pharma, Inc., Astellas Pharma Inc., Cipla Limited, and Pfizer, Inc.[1][4].

5. What are the challenges faced by the anti-itch drug market?

The high cost of treatment and adverse effects associated with some medications are significant challenges[1][4].

Cited Sources:

1. Transparency Market Research Inc. - U.S. Pruritus Treatment Market to Hit USD 8.4 billion by 2031[1].
2. Verified Market Reports - Anti itch Cream Market Size, Share, Growth | Global Industry Trends[2].
3. Grand View Research - Pruritus Therapeutics Market Size And Share Report, 2030[3].
4. Transparency Market Research - U.S. Pruritus Treatment Market Size, Analysis Report 2031[4].